Skip to main content
Journal cover image

Is This a 737 Max Moment for Brolucizumab?

Publication ,  Journal Article
Rosenfeld, PJ; Browning, DJ
Published in: Am J Ophthalmol
August 2020

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Ophthalmol

DOI

EISSN

1879-1891

Publication Date

August 2020

Volume

216

Start / End Page

A7 / A8

Location

United States

Related Subject Headings

  • Wet Macular Degeneration
  • Vascular Endothelial Growth Factor A
  • Uveitis
  • Retinal Vasculitis
  • Ophthalmology & Optometry
  • Intravitreal Injections
  • Humans
  • Drug-Related Side Effects and Adverse Reactions
  • Antibodies, Monoclonal, Humanized
  • Angiogenesis Inhibitors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rosenfeld, P. J., & Browning, D. J. (2020). Is This a 737 Max Moment for Brolucizumab? Am J Ophthalmol, 216, A7–A8. https://doi.org/10.1016/j.ajo.2020.05.012
Rosenfeld, Philip J., and David J. Browning. “Is This a 737 Max Moment for Brolucizumab?Am J Ophthalmol 216 (August 2020): A7–8. https://doi.org/10.1016/j.ajo.2020.05.012.
Rosenfeld PJ, Browning DJ. Is This a 737 Max Moment for Brolucizumab? Am J Ophthalmol. 2020 Aug;216:A7–8.
Rosenfeld, Philip J., and David J. Browning. “Is This a 737 Max Moment for Brolucizumab?Am J Ophthalmol, vol. 216, Aug. 2020, pp. A7–8. Pubmed, doi:10.1016/j.ajo.2020.05.012.
Rosenfeld PJ, Browning DJ. Is This a 737 Max Moment for Brolucizumab? Am J Ophthalmol. 2020 Aug;216:A7–A8.
Journal cover image

Published In

Am J Ophthalmol

DOI

EISSN

1879-1891

Publication Date

August 2020

Volume

216

Start / End Page

A7 / A8

Location

United States

Related Subject Headings

  • Wet Macular Degeneration
  • Vascular Endothelial Growth Factor A
  • Uveitis
  • Retinal Vasculitis
  • Ophthalmology & Optometry
  • Intravitreal Injections
  • Humans
  • Drug-Related Side Effects and Adverse Reactions
  • Antibodies, Monoclonal, Humanized
  • Angiogenesis Inhibitors